17-DMAG, a HSP90 inhibitor, also effectively controlled both resistant cells. Considering a report showing that a HSP90 inhibitor was not clinically effective possibly because of inadequate dose, the efficacy of low dose 17-DMAG was examined. Interestingly, we found that combined treatment of BIBW-2992 with low dose 17-DMAG was very effective even in cells with higher level of T790M although either of both showed no activity in single treatment suggesting it would be one of promising strategies with immediate clinical implications overcoming T790M-mediated resistance.
我看到这一段说，17-DMAG的临床剂量可能太低，导致效果不见得怎么好。但是，2992和低剂量的17-DMAG联用居然很有效果，甚至对于高浓度的T790M突变细胞也非常有效。我有一疑问，17-DMAG是HSP90抑制剂，怎么和2992联用起来居然能对抗T790M，这样的话，是否可以考虑用2992的过程中，间歇的用17-DMAG和2992联用避免耐药。
显身卡
